Mounjaro maker signs $2.7 billion deal on AI drug research
US pharma giant Eli Lilly has agreed to work with a Hong Kong-listed biotech company to use artificial intelligence for drug discovery, according to a stock market filing.
It said the value of the deal between Eli Lilly — known for its weight loss jabs including Mounjaro — and AI software firm Insilico Medicine could be up to US$2.75 billion.
The pair will use Insilico’s “AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas”, said the filing, made by Insilico’s parent company on Sunday.
